article thumbnail

Your Healthcare Compliance Due Diligence Checklist

Compliancy Group

A comprehensive due diligence checklist will cover areas such as licensing requirements, contractual agreements, fraud prevention measures, and risk management protocols. This article provides a general overview but does not constitute legal advice or an exhaustive list of all potential compliance considerations healthcare organizations face.

article thumbnail

Embracing Technology: FDA Releases Draft Guidance on Decentralized Clinical Trials

Hall Render

For health care institutions conducting DCTs, considerations include compliance with fraud and abuse and beneficiary inducement requirements. Hall Render blog posts and articles are intended for informational purposes only.

FDA 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Introduction to Telebehavioral Health

AIHC

This article is not intended as legal or consulting advice. If your practice is currently using a telebehavioral health approach for patient treatment, or if you organization is considering implementing this approach, we hope this article will give some food-for-thought on the topic.

article thumbnail

Is Your Data Supply Chain Ethical? Don’t Restrict Due Diligence to Physical Operations.

C&M Health Law

This article was originally published in Corporate Compliance Insights. bribery, fraud, misuse). Suppose that a biopharmaceutical enterprise submits regulatory approval for a new product, only to realize that the data collected from outsourced clinical trials is based on insufficiently informed consent.

article thumbnail

AI in Healthcare

HIPAA Journal

This article aims to answer the questions what AI in healthcare is, what are – or what will be – the benefits of AI in healthcare, and how can concerns about the ethics of AI in healthcare be overcome. AI is used by the finance industry to detect potential credit card fraud.

article thumbnail

Malarkey ? The Ten Worst Prescription Drug/Medical Device Decisions of 2023

Drug & Device Law

The logic of the consumer fraud claim made no sense. Allegedly, consumers deprived of efficacy (not risk) information had their informed consent rights infringed, which in the case of persons without the genetic difference, meant that they were spared the expense of undergoing negative genetic testing.

FDA 52
article thumbnail

The BFDs – The Ten Best Prescription Drug/Medical Device Decisions of 2023

Drug & Device Law

2023) (First Amendment bars state-law misrepresentation claims over “truth” of published scientific article) ( here ); National Association of Wheat Growers v. 2023) ( Buckman preemption barred MDL asserting fraud on EPA), cert. Plaintiff knew about it, too, since he signed an informed consent document mentioning it.

FDA 105